Open-angle Glaucoma
Open-angle Glaucoma - Related Videos
01:27
Open Angle Glaucoma: Treatment
0 Views •
2023
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow. Drugs such as carbonic anhydrase inhibitors, α2- and...
03:04
Experimental Glaucoma Induction via Iridocorneal Angle Obstruction In a Mouse Model
0 Views •
2025
In this video, an anesthetized rat undergoes an ocular procedure where magnetic beads are injected into the anterior chamber under a magnetic field to block the iridocorneal angle. This blockage obstructs the trabecular meshwork, preventing aqueous humor drainage and leading to increased intraocular pressure, damaging the retinal ganglion cells and optic nerve. This develops a glaucoma-like condition.
01:28
Angle Closure Glaucoma: Treatment
0 Views •
2023
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
07:11
Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
0 Views •
Cited by 3 •
2020
The isolated-check visual evoked potential (icVEP) method is implemented here to assess the magnocellular ON pathway that is initially damaged in glaucoma. The study shows standard operative procedures using icVEP to obtain reliable results. It is proved to serve as a useful objective diagnosing technology for the early detection of glaucoma.
05:05
Ultrasound Cyclo Plasty in Eyes with Glaucoma
0 Views •
Cited by 17 •
2018
Glaucoma is a chronic disease with progressive degeneration of optic nerve fibers resulting in decreased visual field. Elevated intraocular pressure is considered the most important and the only treatable risk factor. This manuscript describes a simple, surgeon-friendly, non-incisional technique, named Ultrasound Cyclo Plasty, for reducing intraocular pressure in glaucoma patients.
FAQs
When aqueous humor exits less effectively through the trabecular meshwork, intraocular pressure can rise and increase stress associated with optic nerve damage. Pharmacological strategies therefore either promote an alternative route, such as uveoscleral outflow, or reduce the amount of aqueous humor produced. These complementary targets address different parts of the pressure-regulation problem.
Prostaglandin analogs lower intraocular pressure primarily by enhancing uveoscleral outflow, which provides an additional route for aqueous humor drainage. Their mechanism differs from treatments that suppress fluid production, making them pharmacologically distinct within the available drug classes. Increasing outflow can help reduce pressure that contributes to progressive retinal ganglion cell and optic nerve damage.
Optic nerve damage and retinal ganglion cell loss can progress even when intraocular pressure falls within a statistically normal range. This means pressure remains an important pharmacological target, but pressure elevation is not the only context in which damage occurs. The distinction helps explain why open-angle glaucoma cannot be understood solely as a disorder of visibly increased pressure.
Beta blockers and carbonic anhydrase inhibitors reduce aqueous humor production, while prostaglandin analogs enhance uveoscleral outflow. Alpha-2 agonists are also listed as pharmacological options for lowering pressure. These classes illustrate two broad approaches: decreasing fluid formation or increasing its exit, allowing treatment to act on different components of aqueous humor regulation.
The central goal is to lower intraocular pressure sufficiently to slow progression of optic nerve damage and preserve visual function. Pharmacological treatment addresses a modifiable pressure-related factor, but it does not reverse established retinal ganglion cell loss. Its value therefore lies in reducing the risk of further damage during a chronic disease course.
Because open-angle glaucoma can cause progressive and irreversible vision loss, pharmacological treatment is directed toward long-term preservation rather than a short-term correction of symptoms. Lowering pressure with agents that alter aqueous humor production or outflow may slow disease progression. This makes the mechanism and sustained therapeutic purpose of each drug class clinically important.